Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 40.89B |
| Revenue (ttm) | 28.16B |
| Net Income (ttm) | 951.57M |
| Shares Out | 3.14B |
| EPS (ttm) | 0.28 |
| PE Ratio | 46.43 |
| Forward PE | 23.04 |
| Dividend | $0.61 (4.69%) |
| Ex-Dividend Date | Mar 27, 2024 |
| Volume | 1,061,128 |
| Open | 13.00 |
| Previous Close | 13.00 |
| Day's Range | 12.95 - 13.04 |
| 52-Week Range | 12.58 - 16.39 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 25, 2024 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]
Full Company ProfileFinancial Performance
In 2023, TAK's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.
Financial numbers in JPY Financial StatementsNews
Takeda Announces New Assignments of Directors
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting,...
Takeda To Keep Pushing for China Biotech Partnership
Takeda Pharmaceutical will continue efforts to forge partnerships with Chinese biotech companies even with some tensions between US and China. Speaking exclusively to Bloomberg, CEO Christophe Weber s...
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW...
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safet...
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treat...
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
Japan's Takeda Pharmaceutical gave India's Sun Pharmaceutical and Cipla the rights to commercialize gastrointestinal drug Vonoprazan in the country.
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
ROCKVILLE, Md. and SUZHOU, China , June 20, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and ...
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Monday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndro...
Takeda's seizure drug fails to meet main goal in late-stage studies
Japan's Takeda said on Monday its experimental drug to treat epileptic disorders failed to meet the main goal in two late-stage studies.
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, dou...
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. Ascentage Pharma to receive an option payment of 100 mill...
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for o...
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that it has expanded its partnership with Partners In Health (PIH), an international nonprofit organization, to support a new in...
Celiac Disease Market and Epidemiology Analysis 2018-2034 with Detailed Profiles of Marketed and Pipeline Drugs, Including KAN-101 (Kanyos Bio) and TIMP-GLIA/TAK 101 (Takeda)
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Celiac Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarke...
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data pr...
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results ...
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recomm...
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of t...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement...
Takeda Pharmaceuticals earnings: profits, EPS down over 50% in Q4 financial results
Japanese pharmaceutical titan Takeda (NYSE: TAK/TSE: 4502) today announced their financial results for Q4 and the full fiscal year of 2023. The company described it in a press release as “a year of si...
Takeda Projects Lower Annual Profit After Quarterly Loss
The Japanese drugmaker reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses.
Japan's Takeda Pharma says full-year profit slumps 56%
Japan's Takeda Pharmaceutical said full-year earnings slumped by 56% as the company focused on rebuilding its drug pipeline to make up for the loss of patent protection for major sellers.
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating ...
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recomm...